Table 3.
Efficacy Outcomes by Insulin Modality Used During Baseline Period
| Baseline |
At or over 13 weeks |
Change from baseline |
||||
|---|---|---|---|---|---|---|
| N | Mean (SD) | N | Mean (SD) | N | Mean (SD) | |
| HbA1c %, mmol/mol | ||||||
| MDI | 35 | 8.0 (1.1) | 33 | 7.2 (0.7) | 33 | −0.72 (0.79) |
| [64 (12)] | [55 (7.7)] | [−7.9 (8.6)] | ||||
| Pump without automation | 23 | 7.7 (1.1) | 25 | 7.0 (0.6) | 23 | −0.62 (0.67) |
| [61 (12)] | [53 (6.6)] | [−6.8 (7.3)] | ||||
| Pump with PLGS | 4 | 7.7 (1.2) | 4 | 7.1 (0.4) | 4 | −0.55 (0.93) |
| [61 (13.1)] | [54 (4.4)] | [−6.0 (10.2)] | ||||
| Pump with HCL | 26 | 7.3 (0.8) | 22 | 7.0 (0.6) | 22 | −0.24 (0.55) |
| [56 (8.7)] | [53 (6.6)] | [−2.6 (6.0)] | ||||
| Mean glucose, mg/dL | ||||||
| MDI | 35 | 192 (33) | 34 | 166 (13) | 34 | −26 (27) |
| Pump without automation | 25 | 180 (34) | 25 | 162 (18) | 25 | −18 (20) |
| Pump with PLGS | 4 | 177 (40) | 4 | 163 (18) | 4 | −14 (26) |
| Pump with HCL | 26 | 170 (26) | 25 | 162 (14) | 25 | −8 (18) |
| % Time in range 70–180 mg/dL | ||||||
| MDI | 35 | 48% (16%) | 34 | 64% (8%) | 34 | 16.7% (13.2%) |
| Pump without automation | 25 | 52% (17%) | 25 | 66% (12%) | 25 | 13.9% (8.6%) |
| Pump with PLGS | 4 | 56% (23%) | 4 | 65% (10%) | 4 | 8.5% (14.4%) |
| Pump with HCL | 26 | 62% (14%) | 25 | 66% (8%) | 25 | 4.3% (11.2%) |
| % Time <54 mg/dL | ||||||
| MDI | 35 | 0.58% (0.88%) | 34 | 0.37% (0.33%) | 34 | −0.22% (0.68%) |
| Pump without PLGS and HCL | 25 | 0.72% (0.79%) | 25 | 0.52% (0.56%) | 25 | −0.20% (0.60%) |
| Pump with PLGS | 4 | 0.56% (0.80%) | 4 | 0.49% (0.42%) | 4 | −0.06% (0.41%) |
| Pump with HCL | 26 | 0.38% (0.46%) | 25 | 0.62% (0.59%) | 25 | 0.23% (0.32%) |
HCL, hybrid closed loop; MDI, multiple daily injections; PLGS, predictive low glucose suspend.